Treatment of pulmonary tuberculosis;Tratamiento de la tuberculosis pulmonar

Anales del Sistema Sanitario de Navarra

Volumn 30, Issue SUPPL. 2, 2007, Pages 99-115

  Boldú Mitjans, Joan ^a   Cebollero, P ^a   Abu, J ^a   De Prado, A ^a  

^a Universidad Pública de Navarra

Author keywords

Retreatments; Secondary effects; Treatment; Tuberculosis

Indexed keywords

CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AGRANULOCYTOSIS; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONVULSION; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; FEVER; GASTRITIS; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEPATITIS; HOSPITALIZATION; HUMAN; HYPERSALIVATION; HYPERSENSITIVITY; HYPERURICEMIA; IMMIGRANT; IMPOTENCE; INSOMNIA; KIDNEY FAILURE; LACTATION; LIVER DISEASE; LUNG TUBERCULOSIS; MIGRAINE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEURITIS; OPTIC NEURITIS; OTOTOXICITY; PARESTHESIA; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PROGNOSIS; PSYCHOSIS; PURPURA; RASH; RETREATMENT; REVIEW; SPLEEN INFARCTION; VERTIGO; VESTIBULAR DISORDER;

ALGORITHMS; ANTITUBERCULAR AGENTS; HUMANS; RECURRENCE; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 34848870972     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Normativa sobre tratamiento y retratamiento de la tuberculosis. Recomendaciones SEPAR. Grupo de trabajo del área TIR de SEPAR. Arch Bronconeumol 2002; 38: 441-445.
2. Programa de prevención y control de la tuberculosis en Navarra. Grupo de trabajo de tuberculosis. Boletín informativo del Instituto de Salud Publica de Navarra( ISP): Julio 2006 No 39, 1-16.
3. Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control; Royal College of Physicians, London, 2006; 1-2.
4. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
5. Guía de la Tuberculosis para Médicos Especialistas. 2003. Caminero Luna, JA. Unión Internacional contra la tuberculosis y enfermedades respiratorias (UICTER). ISBN: 2-914365- 13-6.
6. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. American Thoracic Society. Am J Respir Crit Care Med 2000; 161: S221-S247.
7. Grupo de Trabajo sobre Tuberculosis. Consenso nacional para el control de la tuberculosis en España. Med Clin (Barc) 1992; 98: 24-31.
8. J. CASTILLA, M. URTIAGA, J. HUETO, J. SOLA, I. DORRONSORO, L. TORROBA et al. Evolución en las características epidemiológicas de la tuberculosis en Navarra (1994-2003). An Sist Sanit Navar 2005; 28: 237-245.
9. KHAN A, STERLING TR, REVES R, VERNON A, HORSBURGH CR. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med 2006; 174: 344-348.
10. United States Public Health Service. Hepatic toxicity of pirazinamide used with isoniazide in tuberculosis patients. United States Public Healh Service Tuberculosis therapy trial. Am Rev Respir Dis 1959; 80: 371-387.
11. MALONE RS, FISH DN, SPIEGEL DM, CHILDS JM, PELOQUIN CA. The effect of hemodiálisis on cycloserine, ethionamide, paraminosalicylate and clofazimine. Chest 1999; 116: 984-990.
12. ELLARD GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephrom 1993; 64: 169-181.
13. DAVIDSON PT. Managing tuberculosis during pregnancy. Lancet 1995; 346: 199-200.
14. JANA N, VASISHTA K, JINDAL SK, KHUNNU B, GHOSH K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet 1994; 44: 119-124.
15. VARPELA E. HIETALALAHTI J, ARO M. Streptomycin and dihidrostreptomycin during pregnancy and their effect on the child's inner ear. Scand J Respir Dis 1969; 50: 101-109.
16. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 2nd edition. WHO/TB/97220. Geneva. Switzerland: World Health Organization; 1997. (www.who.int/gth/publications/ttgnp/PDF/th97_220.pdf)
17. ENARSON DA, RIEDER HL, ARNODOTTIS T, TREUCQ A. Tuberculosis guide for low income countries, 4th ed. Paris. International Union Against Tuberculosis and Lung diseases. 1996.
18. SNIDER DE, LAYDE PM, JOHNSON MW, LYLE MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122: 65-79.
19. VAN AALDERERN WH, KNOESTER H, KNOL K. Fulminant hepatitis during treatment with Rifampicin, pyrazinamid and ethambutol. Eur J Paediatrics 1987; 146: 215-343.
20. YEW WW, LEUNG, CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
21. MIGLIORI GB, RAVIGLIONE MC, SCHABERG T, DAVIES PDO, ZELLWEGER JP, GRZEMSKA M ET AL. Task Force of ERS, WHO and the Europe Region of IUATLD. Tuberculosis management in Europe. Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Resp J 1999; 14: 978-992.